S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

IMNM Immunome Inc

11.47

0.00 (0.00%)

Pre Market

Last Updated: 03:01:24

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/15/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrew Glade, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jack P. Higgins

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Immunome Charts.

Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Immunome Charts.

Immunome Inc News

Form 8-K - Current report
Tuesday 29 October 2024 (3 days ago) • Edgar (US Regulatory)

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
Tuesday 29 October 2024 (3 days ago) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Tuesday 22 October 2024 (1 week ago) • Edgar (US Regulatory)

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
Friday 18 October 2024 (2 weeks ago) • Business Wire

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Tuesday 8 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Tuesday 8 October 2024 (3 weeks ago) • Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 8 October 2024 (3 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 September 2024 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 19 September 2024 (1 month ago) • Edgar (US Regulatory)

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Friday 13 September 2024 (2 months ago) • Business Wire

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Thursday 29 August 2024 (2 months ago) • Business Wire

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Wednesday 21 August 2024 (2 months ago) • Edgar (US Regulatory)

More Immunome Inc News Articles

Accredited Solutions (PK)

Anavex Life Sciences

NioCorp Developments

Intergrated Cannabis Sol... (PK)

Net Savings Link (PK)

Apple Rush (PK)

Moon Equity (PK)

CBD Life Sciences (PK)

Lightwave Logic

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions